CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 127 enrolled
Drug / intervention
Cediranib +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01208051
NCT01208051Phase 2Completed
CompareCT.gov

Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer

National Cancer Institute (NCI)·interventional·Posted Sep 23, 2010·Updated Jul 15, 2021

In Brief

A Phase 2 clinical trial evaluating Cediranib, Cediranib Maleate, and 2 other interventions for Refractory Differentiated Thyroid Gland Carcinoma and 4 related conditions. Completed, enrolled 127 participants across 33 sites in 2 countries.

Detailed Summary

This partially randomized phase I/II trial studies the side effects and best dose of cediranib maleate when given together with or without lenalidomide and to see how well they work in treating patients with thyroid cancer. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of thyroid cancer by blocking blood flow to the tumor. It is not yet known whether cediranib maleate is more effective when given together with lenalidomide in treating thyroid cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Follicular Carcinoma, Refractory Thyroid Gland Hurthle Cell Carcinoma, Refractory Thyroid Gland Papillary Carcinoma, Unresectable Thyroid Gland Carcinoma
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 23, 2010
Enrollment StartSep 9, 2010
Primary CompletionFeb 1, 2020
TodayJul 2, 2026
Enrollment to primary: 9.4 yearsPosted 15.8 years ago

Interventions

Cediranibdrug

Given PO

Cediranib Maleatedrug

Given PO

Laboratory Biomarker Analysisother

Correlative studies

Lenalidomidedrug

Given PO